Disease characteristics of patients with rheumatoid arthritis at entry to the study in which they received either infliximab or adalimumab
| Characteristics | Infliximab | Adalimumab |
| No | 35 | 34 |
| Age at onset (years), mean (SD) | 57 (10) | 56 (10) |
| Female, No (%) | 30 (86) | 27 (79) |
| RF positive, No (%) | 24 (69) | 23 (68) |
| DAS28 baseline, mean (SD) | 5.6 (1.2) | 5.7 (1.0) |
| MTX at baseline (%) | 100 | 41* |
| Prednisolone at baseline, No (%) | 10 (29) | 9 (26) |
*Note that 20 patients receiving adalimumab were treated with this drug only (DE018 study, Abbott Inc).
DAS28, 28-joint count Disease Activity Score; MTX, methotrexate; RF, rheumatoid factor.